Videos

Events

References

Building a biologics capabilities network

This article explains how Abzena is building a biologics capabilities network through a slew of acquisitions. GEN May[...] Read more

News

Abzena Appoints Louise Duffy as Senior Vice President and Head of Scientific Project Leadership

Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to GMP services for[...] Read more

Information on Abzena’s Response to COVID-19

This page will remain up to date on Abzena’s response to COVID-19 Last updated 16:15 GMT 8th June 2020 Abzena[...] Read more

Information on Abzena’s Response to COVID-19

This page will remain up to date on Abzena’s response to COVID-19 Last updated 15:00 GMT 17th March 2020 The[...] Read more

Abzena Names Kimball Hall as Chief Operating Officer

Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive[...] Read more

Abzena expands leadership team with Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer

San Diego, USA , 21 June 2019 – Abzena, the leading global biologics and ADC target partner research organization,[...] Read more

Abzena expands management team: appoints Campbell Bunce to the role of Chief Scientific Officer and Bo Adair as Senior Vice President Process and Operations

Cambridge, UK and San Diego, USA, 28 March 2019 – Abzena, the leading global biologics target to GMP partner research[...] Read more

ABZENA ANNOUNCES APPOINTMENT OF ELAINE SAPINOSO AS GLOBAL HEAD OF QUALITY

Addition of experienced leadership in GMP Quality as Abzena increases capacity in biologics and complex small molecule[...] Read more

Abzena announces 20m$ investment into expansion of integrated biotherapeutics offering (Biologics Drug Substance and ADC) and makes key executive appointment

Significant increase in capacity to 2000 L scale in new GMP facility, addition of extra cell line development capacity[...] Read more

Faron Pharmaceuticals Ltd announces that it has filed a Clinical Trial Application (CTA)

Faron Pharmaceuticals Ltd today announced that it has filed a Clinical Trial Application (CTA) for Clevegen®, an ABZENA[...] Read more

Interested in our services? Get In Touch